Peter Boros, Genetic Immunity’s President presented the Company’s pDNA-based platform technology and clinical trial data relating to HIV in front of an esteemed gathering of HIV experts.
As part of the presentation, Genetic Immunity announced the launch of a Phase III clinical trial for the company’s lead product candidate, a therapeutic HIV vaccine, to be conducted at the Moscow City Center for the Prevention and Control of AIDS, with the planned enrollment of up to 200 patients. Upon successful completion, Genetic Immunity plans to apply for marketing approval in the Commonwealth of Independent States (CIS) region.
“It was an honor to have been invited and to present in front of such a highly regarded group of HIV experts from Russia, China and the United States. I believe our presentation was well-received and we are all looking forward to a successful trial completion. If marketing approval is granted, our therapeutic HIV vaccine could introduce a paradigm shift in treating HIV,” stated Boros.
The DermaVir platform contains a novel plasmid DNA that encodes most HIV genes. The vaccine is administered topically using the DermaPrep medical device.
“Mr. Boros gave an excellent presentation about Genetic Immunity’s therapeutic vaccine platform with a special emphasis on the company’s HIV results to date. I look forward to completing the planned Phase III trial, and – upon a successful result – to treating patients with a very promising new vaccine product,” added Professor Alexey Mazus, Head of the Moscow City Center for the Prevention and Control of AIDS.